New England Journal of Medicine · 2024 · 396 citations · 22 references
Life SciencesNeurologyNeuroscienceDementiaGerontologyNeurodegenerationAlzheimer DiseaseBiomarkers Of NeurodegenerationCognitive AgingDementia BiomarkersNeurodegenerative DiseasesNeurodegenerative DisordersAlzheimer Disease ProgressionCognitive BiomarkersHippocampal Atrophy BiomarkersLongitudinal Cognitive DeclineLongitudinal Cohort StudiesMemory Decline TrajectoriesNeurodegenerative Disease BiomarkersPreclinical Dementia Biomarkers
BACKGROUND: Biomarker changes that occur in the period between normal cognition and the diagnosis of sporadic Alzheimer's disease have not been extensively investigated in longitudinal studies. METHODS: We conducted a multicenter, nested case-control study of Alzheimer's disease biomarkers in cognitively normal participants who were enrolled in the China Cognition and Aging Study from January 2000 through December 2020. A subgroup of these participants underwent testing of cerebrospinal fluid (CSF), cognitive assessments, and brain imaging at 2-year-to-3-year intervals. A total of 648 participants in whom Alzheimer's disease developed were matched with 648 participants who had normal cognition, and the temporal trajectories of CSF biochemical marker concentrations, cognitive testing, and imaging were analyzed in the two groups. RESULTS: , 14 years; phosphorylated tau 181, 11 years; total tau, 10 years; neurofilament light chain, 9 years; hippocampal volume, 8 years; and cognitive decline, 6 years. As cognitive impairment progressed, the changes in CSF biomarker levels in the Alzheimer's disease group initially accelerated and then slowed. CONCLUSIONS: In this study involving Chinese participants during the 20 years preceding clinical diagnosis of sporadic Alzheimer's disease, we observed the time courses of CSF biomarkers, the times before diagnosis at which they diverged from the biomarkers from a matched group of participants who remained cognitively normal, and the temporal order in which the biomarkers became abnormal. (Funded by the Key Project of the National Natural Science Foundation of China and others; ClinicalTrials.gov number, NCT03653156.).
22
Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 86.9K citations
Guy M. McKhann, David S. Knopman, Howard Chertkow et al. · Alzheimer s & Dementia · 2011 · 18.8K citations · Full text
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Clifford R. Jack, David S. Knopman, William J. Jagust et al. · The Lancet Neurology · 2009 · 4.8K citations · Full text